Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Torokbalint – page 6

69 clinical trials in Torokbalint, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torokbalint at a glance
69
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

69 trials in Torokbalint

Open in trial search

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer stage IV

Not recruiting

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer limited stage

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage I+1

Not recruiting

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Subcutaneous Pembrolizumab with Hyaluronidase to Intravenous Pembrolizumab and Chemotherapy for First-line Treatment of Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer recurrent

Not recruiting

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Torokbalint

What the registry says about research in the country

01 Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating innovative combination therapies and immunotherapy approaches.

  • Advanced NSCLC Treatments
  • Stage III-IV Cancer Therapies
  • Immunotherapy Combinations

Multiple studies investigating targeted therapies for various stages of lung cancer, particularly focusing on patients with specific genetic markers and PD-L1 expression levels.

02 Respiratory Conditions

Research initiatives addressing chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), testing new therapeutic approaches.

  • Uncontrolled Asthma Management
  • COPD Treatment Optimization
  • Cystic Fibrosis Therapies

Studies evaluating novel medications and combination therapies to improve patient outcomes in chronic respiratory conditions.

03 Innovative Therapeutics

Cutting-edge research examining novel drug combinations and treatment approaches, including targeted therapies and immunotherapy agents.

  • Combination Immunotherapies
  • Targeted Molecular Therapies
  • Maintenance Treatment Strategies

Focus on developing personalized treatment approaches based on specific biomarkers and genetic profiles.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.